Novarter announces latest research and development pipeline: Which new drugs are worth paying attention to?

In the short term, important pipeline (non-cancer) Iptacopan (LNP023) is a potential "first-in-class" oral therapy that targets alternative complement pathways, suppressing factor B in the pathways.
is expected to treat four rare kidney diseases and one rare blood disease.
October, Novaral announced that it had significantly reduced proteinuria levels in patients with C3G in Phase 2 clinical trials treating patients with C3G, resulting in positive medium-term clinical results.
is expected to launch the first Phase 3 clinical trial of the therapy in December, treating pNH, and Phase 3 clinical trials of other diseases are expected to start in the first half of next year.
expected to submit a listing application for the treatment by 2023.
IScalimab (CFZ533) is an all-human monoclonal antibody that blocks the CD154-CD40 signaling path.
CD154-CD40 signaling path, which is thought to be associated with a variety of autoimmune diseases, plays an important role in a variety of immune cell functions.
the therapy has been proven in patients with dry syndrome (Sjögren's syndrome, the second largest autoimmune disease after rheumatoid arthritis) and in patients with kidney transplants.
believes iscalimab is expected to be the "first-in-class" treatment for both diseases, with Phase 3 clinical trials expected to start in 2023.
Ligelizumab (QGE031) targets IgE and suppresses the IgE/Fc-RI path.
is expected to be a first-line treatment for chronic spontaneous urticaria (CSU), which is ineffective against histamines.
last year, in a Phase 2b trial, more patients had their symptoms fully alleviated than the company's other drug, Xmalizumab.
Phase 3 clinical data from Ligelizumab is expected in the second half of next year.
Peracarsen (TQJ230) is an anthopedic oligonucleotide (ASO) therapy that reduces the expression of lipoprotein a, thereby reducing the risk of cardiovascular disease.
Phase 2b clinical trial data show that 98% of patients with cardiovascular disease were able to have lipoprotein a level of no higher than 50 mg/dL after treatment.
its two Phase 3 clinical trials will be completed in 2021 and 2024, respectively.
Branaplam (LMI070) is an oral RNA-cut small molecule regulator that is expected to be used in the treatment of Huntington's disease and spinal muscular dystrophy (SMA).
in Huntington's disease, Branaplam has been initially proof of concept to reduce levels of toxic mRNA molecules.
phase 1 clinical trial will be announced in the first half of next year.
SMA, preliminary results show a positive yield/risk ratio.
the results of its Phase 1/2 clinical trial will also be announced in the first half of next year.
canakinumab (ACZ885), an important pipeline (cancer) in the short term, is a monoclonal antibody targeting IL-1 beta.
could be an innovative treatment to address the unfinished needs of patients with stage 2-4 (stage II-IV) non-small cell lung cancer (NSCLC).
the therapy's therapeutic philosophy is to aid the treatment of cancer patients by reducing the inflammatory response that promotes tumor growth.
the drug is currently in Phase 3 clinical trials, with specific data expected to be released next year.
177Lu-PSMA-617 is an emerging radiological ligand therapy that targets prostate-specific membrane antigens (PSMA).
therapy can be delivered specific to cancer cells, promising to treat metastatic despocy resistant prostate cancer (mCRPC).
in Phase 2 clinical trials, the treatment has shown positive results.
its Phase 3 clinical trial results are expected in the first half of 2021.
Sabatolimab (MBG453) is a potential "first-in-class" monoclonal antibody that targets TIM-3 subjects.
these subjects are mostly expressed on the surface of immune cells and myeloid leukemia cells, and their levels are associated with the severity of acute myeloid leukemia (AML) and myeloid growth syndrome (MDS).
this therapy can innovatively target both myeloid leukemia cells and immune cells, not only to kill cancer cells, but also to enhance the vitality of immune cells.
its Critical Phase 2 clinical process and is expected to receive results in the second half of next year and submit its first relevant application.
TNO155 is a low molecular weight SHP2 inhibitor, currently in phase 2 clinical stage.
SHP2 is an important tyrosine phosphatase that regulates the growth signaling path of cancer cells, but inhibitors that traditionally target the active points of phosphatase either fail to enter cells or have strong toxic side effects.
TNO155 is like a "molecular glue" that regulates SHP2 heterogeneously.
is also the first SHP2 inhibitor to enter the clinical phase, novart said.
early trials, it was used in early trials with Mirati Therapeutics' KRAS inhibitor MRTX849, demonstrating potential in treating cancer patients with KRAS G12C mutations.
LXH254 is an innovative in-study therapy and a low molecular weight molecule that inhibits B/C-RAF.
novarma points out that 40 percent of skin melanomas have BRAF mutations and 20 percent have NRAS mutations.
for the former, current therapies are prone to drug resistance.
for the latter, there is a lack of effective therapies in addition to first-line immunotherapy.
, the therapy promises to be a B/C-RAF inhibitor for "best-in-class."
melanoma, it is also expected to be used in the treatment of specific lung cancers.
high-risk, high-return CSJ117 is a human-to-antibody fragment that promises to treat asthma, targeting TSLP, a cytokine involved in asthma-related airway inflammation.
it will be inhaled through dry powder and will reach the lungs directly.
therapy is currently recruiting people with severe asthma in Phase 2b clinical trials.
ECF834 is a recombined human lubricin protein.
normal, it is common on the surface of the eye and has anti-inflammatory and lubrication effects.
is looking forward to using this treatment to treat dry eyes.
patients with moderate to severe dry eye disease, they continue to work quickly and with long-lasting drug therapies.
the second half of 2021, we expect to see phase 2b clinical results.
LNA043 is a modified ANGPTL3 protein that, after injections in the joints, is expected to repair cartilage damage, which is the cause of osteoarthritis.
, there is no treatment for osteoarthritis that prevents joint degeneration.
is expected to launch a Phase 2b clinical trial next year.
QBW251 is an oral CFTR enhancer that improves symptoms of COPD by enhancing lung mucus removal and reducing lung infections.
several COPD therapies have been approved, patients still develop severe symptoms that affect their quality of life.
the second half of next year, the results of its Phase 2b clinical trials are expected to be announced.
NIS793 is an all-human anti-TGF beta IgG2 monoclonal antibody that inhibits the TGF beta path path of tumor cells and regulates the tumor micro-environment, reversing immunosuppression and fibrosis.
didn't release much details, only that NIS793 was used to treat solid tumors, and just completed its first volunteer visit (FPFV) in October.
addition to these advances, Novart has introduced other emerging therapies and expanded the development of approved therapeutic adaptations.
: s1. Meet Novartis Management 2020, Retrieved November 24, 2020, from